Over the counter asthma inhalers effectiveness
Pro Research Analysisby 
Searched over 200M research papers
Over-the-Counter Asthma Inhalers: Effectiveness and Safety
OTC Asthma Inhalers: Types and Usage Patterns
Over-the-counter (OTC) asthma inhalers, particularly those containing short-acting beta-2 agonists (SABA) like epinephrine, are widely available in some countries and are often used by individuals with mild, intermittent asthma for quick symptom relief Dickinson2000Aschenbrenner2019. However, studies show that a significant proportion of users have more persistent or severe asthma, for which OTC inhalers are not recommended as the sole therapy Dickinson2000Loh2023. Many patients self-medicate with OTC inhalers, sometimes without proper diagnosis or assessment, leading to potential misuse and overuse Khalil2024Loh2023.
Effectiveness of OTC Epinephrine and SABA Inhalers
When used as directed for mild, intermittent asthma, OTC epinephrine inhalers can provide effective short-term relief of symptoms . However, their effectiveness is limited compared to modern inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combinations, especially for preventing severe asthma attacks and maintaining long-term asthma control Ho2023Beasley2022Park2022. There is low-quality evidence supporting the efficacy of epinephrine compared to selective beta-2 agonists, and epinephrine does not address underlying airway inflammation .
Risks and Adverse Outcomes of OTC Inhaler Overuse
Multiple studies highlight that overuse of OTC SABA inhalers is common and associated with poor asthma control, increased risk of severe exacerbations, more frequent emergency room visits, and even increased risk of asthma-related death Price2024Khalil2024Loh2023. Overuse is particularly problematic among patients with moderate-to-severe asthma who are not using preventer medications like ICS Price2024Khalil2024Loh2023. Many users are unaware of the risks of SABA overuse, and lack of education contributes to unsafe practices Loh2023Hussain2025.
Comparative Effectiveness: ICS/Formoterol vs. OTC Epinephrine
Recent research suggests that if ICS/formoterol (a combination of inhaled corticosteroid and long-acting beta-agonist) were made available OTC, it would be a much more effective and safer option than OTC epinephrine Ho2023Beasley2022. As-needed ICS/formoterol reduces the risk of severe exacerbations by 32–55% compared to SABA alone, improves asthma control, and lowers the risk of asthma-related death Ho2023Beasley2022Park2022. Network meta-analyses rank ICS/LABA regimens higher than SABA-only regimens for preventing exacerbations and improving lung function Beasley2022Park2022. Additionally, ICS/formoterol has fewer systemic side effects compared to repeated high doses of SABA .
Patient and Pharmacist Perspectives
Patients often rely on OTC inhalers for immediate relief and may not see the need for regular physician follow-up, while pharmacists express concern about the frequency and technique of SABA use . Both groups recognize that good asthma control is linked to reduced reliance on SABA inhalers, but barriers such as health literacy and lack of education persist .
Conclusion
OTC asthma inhalers, especially those containing SABA or epinephrine, can provide short-term relief for mild, intermittent asthma when used correctly. However, their overuse is linked to poor asthma outcomes, increased exacerbations, and higher healthcare utilization. Modern ICS/LABA combinations, if made available OTC, would offer superior effectiveness and safety, particularly for underinsured or disadvantaged populations. Improved patient education and regular asthma management are essential to minimize the risks associated with OTC inhaler use and to ensure optimal asthma control Ho2023Beasley2022Price2024+4 MORE.
Sources and full results
Most relevant research papers on this topic
Cost-effectiveness of budesonide-formoterol versus inhaled epinephrine in United States adults with mild asthma.
OTC as-needed budesonide-formoterol for treating mild asthma in underinsured adults without HCP management improves asthma outcomes, prevents fatalities, and is cost-saving.
DOI